Keros Therapeutics (NASDAQ:KROS) Receives “Neutral” Rating from Wedbush

Wedbush reaffirmed their neutral rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $15.00 target price on the stock.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company dropped their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th. TD Cowen downgraded shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Cantor Fitzgerald lowered shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Keros Therapeutics in a research report on Tuesday. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.33.

Keros Therapeutics Trading Up 2.4 %

KROS stock opened at $10.28 on Tuesday. Keros Therapeutics has a 12-month low of $9.41 and a 12-month high of $72.37. The business’s 50-day moving average is $11.04 and its 200 day moving average is $33.31. The stock has a market cap of $416.98 million, a price-to-earnings ratio of -1.97 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. As a group, equities analysts forecast that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. AlphaQuest LLC increased its stake in Keros Therapeutics by 469.0% during the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after acquiring an additional 2,964 shares during the last quarter. Virtus ETF Advisers LLC grew its holdings in shares of Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Keros Therapeutics during the 4th quarter worth $90,000. Exchange Traded Concepts LLC acquired a new stake in shares of Keros Therapeutics during the 4th quarter worth about $99,000. Finally, CANADA LIFE ASSURANCE Co raised its holdings in Keros Therapeutics by 207.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company’s stock valued at $116,000 after buying an additional 4,976 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.